Mesoblast (MESO) Other Gross PP&E Adjustments (2019 - 2025)
Mesoblast recorded quarterly Other Gross PP&E Adjustments of -$6.5 million in Q4 2025, down 57.39% quarter-over-quarter from -$4.1 million in Q2 2025, and down 133.73% year-over-year from $19.2 million in Q4 2024.
Mesoblast's Other Gross PP&E Adjustments history runs 7 years deep, the most recent figure standing at -$6.5 million for Q4 2025.
- In Q4 2025, Other Gross PP&E Adjustments fell 133.73% year-over-year to -$6.5 million; the TTM figure through Dec 2025 stood at -$6.5 million (down 133.73% YoY), while the FY2025 annual figure was -$4.1 million, down 50.84% from the prior year.
- Other Gross PP&E Adjustments came in at -$6.5 million for Q4 2025 at Mesoblast, down from -$4.1 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$2.7 million in Q2 2024 to a low of -$9.1 million in Q2 2021.
- A 5-year average of -$6.2 million and a median of -$6.5 million in 2025 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments surged 46.79% in 2024 and slumped 133.73% in 2025, its largest moves.
- Mesoblast's Other Gross PP&E Adjustments stood at -$9.0 million in 2021, then surged by 38.61% to -$5.5 million in 2022, then soared by 42.2% to -$3.2 million in 2023, then gained by 13.42% to -$2.8 million in 2024, then plunged by 133.73% to -$6.5 million in 2025.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$6.5 million, -$4.1 million, and -$2.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | -6.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.49 Mn |
| Dec 31, 2025 | -6.49 Mn |
| Jun 30, 2025 | -4.12 Mn |
| Jun 30, 2025 | -4.12 Mn |
| Dec 31, 2024 | -2.78 Mn |
| Dec 31, 2024 | -2.78 Mn |
| Jun 30, 2024 | -2.73 Mn |
| Jun 30, 2024 | -2.73 Mn |
| Dec 31, 2023 | -3.21 Mn |
| Dec 31, 2023 | -3.21 Mn |
| Jun 30, 2023 | -5.13 Mn |
| Jun 30, 2023 | -5.13 Mn |
| Mar 31, 2023 | -5.64 Mn |
| Mar 31, 2023 | -5.64 Mn |
| Dec 31, 2022 | -5.55 Mn |
| Dec 31, 2022 | -5.55 Mn |
| Sep 30, 2022 | -7.73 Mn |
| Sep 30, 2022 | -7.73 Mn |
| Jun 30, 2022 | -7.92 Mn |
| Jun 30, 2022 | -7.92 Mn |
| Mar 31, 2022 | -8.36 Mn |
| Mar 31, 2022 | -8.36 Mn |
| Dec 31, 2021 | -9.03 Mn |
| Dec 31, 2021 | -9.03 Mn |
| Sep 30, 2021 | -8.49 Mn |
| Sep 30, 2021 | -8.49 Mn |
| Jun 30, 2021 | -9.12 Mn |
| Jun 30, 2021 | -9.12 Mn |
| Mar 31, 2021 | -7.25 Mn |
| Mar 31, 2021 | -7.25 Mn |
| Dec 31, 2020 | -7.18 Mn |
| Dec 31, 2020 | -7.18 Mn |
| Sep 30, 2020 | -8.04 Mn |
| Sep 30, 2020 | -8.04 Mn |
| Jun 30, 2020 | -7.98 Mn |
| Jun 30, 2020 | -7.98 Mn |
| Mar 31, 2020 | -7.48 Mn |
| Mar 31, 2020 | -7.48 Mn |
| Dec 31, 2019 | -8.04 Mn |
| Dec 31, 2019 | -8.04 Mn |
| Sep 30, 2019 | -4.23 Mn |
| Sep 30, 2019 | -4.23 Mn |